What are the common medications prescribed by dermatologists for psoriasis?

Psoriasis is a chronic, immune-mediated inflammatory condition that affects the skin and sometimes the joints. It is not simply a dry skin issue. It results from an overactive immune system that speeds up the growth cycle of skin cells, leading to the buildup of thick, red, scaly plaques. Dermatologists rely on a range of evidence-based prescription medications to manage symptoms, reduce inflammation, and slow cell turnover. The choice of treatment depends on the severity of the psoriasis, the location of plaques, and the patient's overall health. Generally, medications fall into three categories: topical treatments for mild to moderate cases, phototherapy, and systemic medications or biologics for moderate to severe disease.

For mild to moderate psoriasis, topical treatments are the first line of therapy. Corticosteroids are the most commonly prescribed. They reduce inflammation and itching, with potency ranging from low (for sensitive areas like the face or groin) to high (for thick plaques on the trunk or limbs). Another key class is vitamin D analogues, such as calcipotriene, which slow cell growth and help normalize the skin. Combination products, like calcipotriene with betamethasone, are also frequently used to enhance efficacy. Topical calcineurin inhibitors, such as tacrolimus and pimecrolimus, are reserved for sensitive areas because they lack the side effects of steroids. Coal tar and anthralin are older options that remain effective for some patients, though they are less commonly prescribed now due to staining and messiness.

For moderate to severe cases, or when topical treatments fail, phototherapy is a standard approach. Narrowband UVB light therapy is the most common form. It is delivered in a dermatologist’s office or via a home unit under medical supervision. This treatment works by suppressing the immune response in the skin. PUVA (psoralen plus UVA) combines a light-sensitizing medication with UVA light and is also effective, though used less often due to long-term skin cancer risks. Data from clinical studies show that narrowband UVB can clear psoriasis in 60-80% of patients after 20-30 sessions.

Systemic and Biologic Medications

When psoriasis is widespread or resistant to other treatments, dermatologists prescribe systemic medications. Traditional oral agents include methotrexate, cyclosporine, and acitretin. Methotrexate is a folate antagonist that reduces cell turnover and inflammation; it requires regular blood monitoring. Cyclosporine is a powerful immunosuppressant often used for short-term control due to potential kidney and blood pressure side effects. Acitretin, an oral retinoid, is particularly useful for pustular psoriasis and is sometimes combined with phototherapy. These drugs have been used for decades with well-studied safety profiles.

Biologic drugs represent a major advance in psoriasis management. These are injectable or intravenous medications that target specific immune pathways. The most common classes include tumor necrosis factor (TNF) inhibitors, such as adalimumab and etanercept; interleukin (IL)-17 inhibitors, such as secukinumab and ixekizumab; IL-23 inhibitors, such as guselkumab and risankizumab; and IL-12/23 inhibitors, such as ustekinumab. Clinical trials have demonstrated that many biologics achieve clear or almost clear skin (PASI 90 or PASI 100) in a significant proportion of patients. For instance, with risankizumab, more than 80% of patients achieved PASI 90 in pivotal studies. Biologics are generally well tolerated, but they require careful screening for infections like tuberculosis and regular follow-up.

In addition to these, a newer class of oral small molecules, such as apremilast and deucravacitinib, offers an alternative for moderate disease. Apremilast works by inhibiting phosphodiesterase 4, reducing inflammation. Deucravacitinib targets tyrosine kinase 2 (TYK2) and has shown strong efficacy with a favorable safety profile in clinical studies. Both are taken as pills and avoid the need for injections.

It is critical to remember that no single medication works for everyone. The best treatment plan is a personalized decision made with a board-certified dermatologist. Patients should not adjust or stop their medications without medical guidance, as this can lead to flare-ups or adverse effects. For long-term management, dermatologists may rotate therapies or combine them to maintain control and minimize side effects. Regular follow-up and open communication with your dermatologist are essential for achieving the best outcomes.